Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.

FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

The median overall survival in the total population was 10.3 months (95% confidence interval [CI], 8.0 to 11.8) in the pembrolizumab group, as compared with 7.4 months (95% CI, 6.1 to 8.3 ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC ...

Safety was a secondary end point. A total of 496 patients were randomly assigned to receive pembrolizumab, and 498 to receive placebo. At the prespecified interim analysis, the median time from ...

The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous ...